Coronavirus Update: Moderna Could Have Advantage Over Pfizer’s Cold Chain

Plus: BioNTech Signs Asia Deal

 
• By Scrip Team

Cold chain distribution requirements are a major downside for mRNA-based vaccines, but Moderna may have the edge over Pfizer/BioNTech's candidate.

Bottles coronavirus vaccine. sars-cov-2 / COVID-19. Some ampoules with ncov-2019 vaccine in a box. to fight the coronavirus pandemic.
Both frontrunner mRNA vaccines require refrigeration - but Pfizer's must be kept at -70°C, which could prove to be a barrier to distribution.

More from COVID-19

More from Scrip